Skip to content

Beta-alanine Supplementation and Its Effects on Performance, Muscle Carnosine Content and Safety in Athletes With Spinal-cord Injury

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02604927
Enrollment
20
Registered
2015-11-16
Start date
2016-02-29
Completion date
2017-09-30
Last updated
2015-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Brief summary

Paralympians competing in wheelchair sports may experience a very high glycolytic demand (and therefore acidotic environment) in their upper-body muscles, particularly in high-intensity disciplines. Previous studies from our group have shown that upper-body exercise is very sensitive to the ergogenic effects of β-alanine supplementation and to other nutritional supplements capable of increasing buffering capacity. In line with this, have shown that upper-body muscle groups benefit more from artificially induced alkalosis than lower-body muscle groups. Although β-alanine appears to be an interesting and potential ergogenic supplement for paralympians, no study to date has assessed its potential in wheelchair athletes.In this study, we will evaluate the effects of β-alanine supplementation on upper-body performance in wheelchair athletes.

Interventions

DIETARY_SUPPLEMENTBeta-alanine
DIETARY_SUPPLEMENTDextrose

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Paralympian training for any exercise modality for at least one year; * A weekly training volume of 6 hours or more; * Have a spinal cord injury accompanied by loss of motor function in the lower limbs for at least one year; * Available for carrying out the experimental procedures.

Exclusion criteria

* Use of creatine or beta-alanine for at least 3 and 6 months before the trial; * Cardiovascular or respiratory disease; * Clinical condition that result in malabsorption of nutrients; * Any other medical condition that prevents the realization of experimental procedures.

Design outcomes

Primary

MeasureTime frameDescription
Exercise performance (Time to exhaustion test)28 daysTime to exhaustion test performed on arm crank ergometer
Muscle carnosine content before and after supplementation28 daysAssessed by muscle biopsy samples before performance tests

Secondary

MeasureTime frameDescription
Muscle carnosine content in trained (deltoid) vs. untrained (vastus lateralis) muscles28 daysDeltoids microbiopsy and vastus lateralis biopsy
Blood pH.5 minutes after performance tests1 mL venous blood sample
Safety of beta-alanine supplementation measured by complete hemogram analysis28 days

Countries

Brazil

Contacts

Primary ContactGuilherme Artioli, PhD
artioli@usp.br55 11 30913096

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026